---
title: Hypertensive Pregnant Women Monitored by Teletransmitted Self-measurements of Blood Pressure
nct_id: NCT03648645
overall_status: UNKNOWN
phase: NA
sponsor: Rennes University Hospital
study_type: INTERVENTIONAL
primary_condition: Hypertension in Pregnancy
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03648645.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03648645"
ct_last_update_post_date: 2023-07-28
last_seen_at: "2026-05-12T07:12:29.113Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Hypertensive Pregnant Women Monitored by Teletransmitted Self-measurements of Blood Pressure

**NCT ID:** [NCT03648645](https://clinicaltrials.gov/study/NCT03648645)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Rennes University Hospital
- **Conditions:** Hypertension in Pregnancy
- **Start Date:** 2022-05-25
- **Completion Date:** 2023-11-01
- **CT.gov Last Update:** 2023-07-28

## Brief Summary

The occurrence of arterial hypertension (AH) during pregnancy is a major cause of fetal, neonatal and maternal morbidity and mortality in western countries. It is estimated that about 10% of pregnancies are complicated by AH (80 000 women / year in France). It is therefore essential to diagnose AH with certainty in order to set-up appropriate care and follow its evolution.

## Detailed Description

The objective of this study is to show the faisability of self-measurement with teletransmission for long-term follow-up of hypertensive pregnant women (at high risk of preeclampsia) by avoiding repeated, prolonged visits or hospitalizations and to optimize the intervention of health professionals by providing them with reliable data.

A multicenter, controlled study will be conducted in women presenting with mild to moderate hypertension without preeclampsia followed throughout their pregnancy by either self-measurement with teletransmission.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Pregnant women with confirmed mild to moderate AH untreated and / or under antihypertensive treatment (for gestational or chronic hypertension)
* Women without preeclampsia requiring enhanced AH surveillance
* Patient affiliated to a social security system
* Patient giving consent to participate in the study.
* Age\> 18 years

Exclusion Criteria:

* arm circumference greater than 42 cm unsuitable for self-measurement,
* women in atrial fibrillation, or frequently in arrhythmia, with secondary hypertension or severe hypertension or with cardiovascular complication.
* women having preeclampsia.
* women having an AH by "white coat effect".
* women having a move or maternity change planned during pregnancy.
* majors protected under tutorship or curatorship, or under the protection of justice.
```

## Arms

- **AH Telemonitoring** (EXPERIMENTAL) — Self measurement of blood pressure

## Interventions

- **Self measurement of blood pressure** (DEVICE) — Patients will perform the measurement of blood pressure at home, on a daily basis, in complying with the "rule of 3" stated by the Haute Autorité de Santé (French Health Authority) : i.e. 3 consecutive measurements in the morning and in the evening, after a period of rest Measurements are performed using a blood pressure monitor Bluetooth-connected. If a threshold value is exceeded (and depending on the alert), a consultation will be scheduled (unexpected consultation) and notified to the patient.

## Primary Outcomes

- **Hypertension specific intervention** _(time frame: Through study completion, an average of 9 months)_ — Percentage of blood pressure measurements initially planned and actually performed during the course of the investigation

## Secondary Outcomes

- **Number of blood pressure measurements per day and per week** _(time frame: Through study completion, an average of 9 months)_
- **Likert scale to assess patients' satisfaction** _(time frame: Through study completion, an average of 9 months)_
- **Likert scale to assess medical staff's satisfaction** _(time frame: Through study completion, an average of 9 months)_

## Locations (5)

- CHU Caen, Caen, France
- CHU Lille, Lille, France
- Hôpital Cochin (APHP), Paris, France
- CH St-Malo, St-Malo, France
- CHU Tours, Tours, France

## Recent Field Changes (last 30 days)

- `armsInterventions.arms` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.chu caen|caen||france` — added _(2026-05-12)_
- `locations.chu lille|lille||france` — added _(2026-05-12)_
- `locations.hôpital cochin (aphp)|paris||france` — added _(2026-05-12)_
- `locations.ch st-malo|st-malo||france` — added _(2026-05-12)_
- `locations.chu tours|tours||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03648645.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03648645*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*